Updates in Anterior Segment and Oculoplastic Surgery
Date: 20/03/2019
Venue: The European 161 Spring Street, Melbourne, VIC, 3000
Provider: Novartis Pharmaceuticals Australia Pty Ltd - NSW
Contact: Robyn Lally, [E] robyn.lally@novartis.com, [P] 0447868717
Learning Objectives
- In attending this CPD presentation the attendee will be introduced to the latest in management trends in Fuchs Endothelial Dystrophy. This will result in early recognition, timely referrals and ultimately the best outcomes for patients with these problems.
- In attending this presentation the attendee will be given an update on the latest trends in ophthalmic and Oculoplastic Surgery and enhance the optometrists ability to recognise and refer important neurological and medical conditions.
- In attending this CPD presentation the attendee will be introduced to the latest in management trends in Keratoconus. This will result in early recognition, timely referrals and the best outcomes for patients.
Max points awarded: 3.67
Session Information
| Name |
|---|
| Restoring function and look in ophthalmic and Oculoplastic surgery |
| Activity Type |
| Face to Face without Assessment |
| Therapeutic? |
| No |
| Manufacturer/Supplier? |
| No |
| Points for attending & Passing Assessment |
| 1.50 |
| Name |
|---|
| The latest in management trends in Fuchs Endothelial Dystrophy and Keratoconus. |
| Activity Type |
| Face to Face without Assessment |
| Therapeutic? |
| No |
| Manufacturer/Supplier? |
| No |
| Points for attending & Passing Assessment |
| 1.50 |
| Name |
|---|
| Question and Answer Session |
| Activity Type |
| Face to Face without Assessment |
| Therapeutic? |
| No |
| Manufacturer/Supplier? |
| No |
| Points for attending & Passing Assessment |
| 0.67 |
| Name | Activity Type | Therapeutic? | Manufacturer/ Supplier? | Points for attending & Passing Assessment |
|---|---|---|---|---|
| Restoring function and look in ophthalmic and Oculoplastic surgery | Face to Face without Assessment | No | No | 1.50 |
| The latest in management trends in Fuchs Endothelial Dystrophy and Keratoconus. | Face to Face without Assessment | No | No | 1.50 |
| Question and Answer Session | Face to Face without Assessment | No | No | 0.67 |